Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00558103 · ClinicalTrials.gov registry record · Phase 2
Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Inflammatory Breast Cancer
A Phase 2 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 2
- Development phase
- 163
- Enrollment target
NCT00558103 is a Phase 2 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 163 participants.
The verdict
NCT00558103, a Phase 2 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 163 participants
- Enrollment target
Study Summary
The double blind part of the study is being conducted to compare the efficacy and safety of pazopanib in combination with lapatinib with that of lapatinib alone in subjects with inflammatory breast cancer whose tumors overexpress the ErbB2 protein. There is also an Open-label pazopanib arm to this study designed to test whether pazopanib given alone and lapatinib given alone would be safe and effective to treat patients with inflammatory breast cancer.
Interventions
- DRUG Pazopanib
- DRUG lapatinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 163 participants |
| Start Date | 2007-12 |
| Est. Completion | 2011-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00558103
The ClinicalTrials.gov registry entry for NCT00558103 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 163 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Pazopanib is the first listed.
NCT00558103 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00558103 about?
NCT00558103 is a clinical study titled "Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Inflammatory Breast Cancer". The double blind part of the study is being conducted to compare the efficacy and safety of pazopanib in combination with lapatinib with that of lapatinib alone in subjects with inflammatory breast cancer whose tumors overexpress the ErbB2 protein. There is also an Open-label pazopanib arm to this s...
What is the current status of trial NCT00558103?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 163 participants. The study started on 2007-12. Estimated completion is 2011-12.
What interventions are being tested in trial NCT00558103?
The interventions under investigation include: Pazopanib (DRUG), lapatinib (DRUG).
Who is sponsoring clinical trial NCT00558103?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.